



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

In re Application of: :

KAESEMEYER : Confirmation No. 7600

Serial No. 10/763,358 : Group Art Unit: 1614

Filed: January 23, 2004 : Examiner: Not Assigned

For: COMPOSITIONS COMPRISING ARGININE AND NITRATES

Date Mailed: November 2, 2006

I HEREBY CERTIFY THAT THIS SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.8 AND IS ADDRESSED TO MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

Kathleen Pujol

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

Documents Mailed:

Supplemental Information Disclosure Statement (2 pages)

Form PTO-1449 (5 pages)

References Cited (101)

Certificate of Mailing

Postcard

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In the Application of:

KAESEMEYER

Serial No. 10/763,358

Filed: January 23, 2004

: Confirmation No. 7600

: Group Art Unit: 1614

: Examiner: Not Yet Assigned

For: COMPOSITIONS COMPRISING ARGININE AND NITRATES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP



Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Telephone: (412) 454-5000
Facsimile: (412) 281-0717
Date: November 2, 2006



PATENT

| | | | | | |
|------------------------------|---|----|---|------------------------|------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/763,358 |
| | | | | Filing Date | January 23, 2004 |
| | | | | First Named Inventor | Kaesemeyer |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 5 | Attorney Docket Number | 126625.00901 |

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---------------------|-----------|----------------------|----------------------|---|--|---|
| | | Number | Kind Code (if known) | | | |
| A1 | 5,286,739 | | | Kilbourn et al. | 02-15-1994 | |
| A2 | 5,281,627 | | | Griffith | 01-25-1994 | |
| A3 | 5,273,875 | | | Griffith | 12-28-1993 | |
| A4 | 5,266,594 | | | Dawson et al. | 11-30-1993 | |
| A5 | 5,196,195 | | | Griffith | 03-23-1993 | |
| A6 | 5,158,883 | | | Griffith | 10-27-1992 | |
| A7 | 5,132,453 | | | Griffith | 07-21-1992 | |
| A8 | 5,132,407 | | | Stuehr et al. | 07-21-1992 | |
| A9 | 5,059,712 | | | Griffith | 10-22-1991 | |
| A10 | 4,686,211 | | | Hara et al. | 08-11-1987 | |
| A11 | 5,428,070 | | | Cooke et al. | 06-27-1995 | |
| A12 | 5,830,879 | | | Isner | 11-03-1998 | |
| A13 | 5,795,898 | | | Brown et al. | 08-18-1998 | |
| A14 | 5,543,430 | | | Kaesemeyer | 08-06-1996 | |
| A15 | 5,428,070 | | | Cooke et al. | 06-27-1995 | |
| A16 | 5,147,650 | | | Fregly et al. | 09-15-1992 | |
| A17 | 4,920,098 | | | Cotter et al. | 04-24-1990 | |
| A18 | 5,106,836 | | | Clemens et al. | 04-21-1992 | |
| A19 | 5,171,217 | | | March et al. | 12-15-1992 | |
| A20 | 5,278,189 | | | Rath et al. | 01-11-1994 | |
| A21 | 5,366,738 | | | Rork et al. | 11-22-1994 | |
| A22 | 5,620,876 | | | Davis et al. | 04-15-1997 | |
| A23 | 5,650,418 | | | Rath et al. | 07-22-1997 | |
| A24 | 5,852,058 | | | Cooke et al. | 12-22-1998 | |
| A25 | 5,861,168 | | | Cooke et al. | 01-19-1999 | |
| A26 | 5,891,459 | | | Cooke et al. | 04-06-1999 | |
| A27 | 5,595,970 | | | Garfield et al. | 07-01-1997 | |
| A28 | 6,425,881 | | | Kaesemeyer | 07-30-2002 | |
| A29 | 5,824,331 | | | Usala | 10-20-1998 | |
| A30 | 5,895,663 | | | Irwin et al. | 04-20-1999 | |
| A31 | 4,940,580 | | | Sangekar et al. | 07-10-1990 | |
| A32 | 4,983,398 | | | Gaylord et al. | 01-08-1991 | |
| A33 | 4,967,658 | | | Townsend | 11-06-1990 | |
| A34 | 5,582,838 | | | Rork et al. | 12-10-1996 | |
| A35 | 5,508,045 | | | Garfield et al. | 01-21-1997 | |
| A36 | 5,643,944 | | | Garfield et al. | 07-01-1997 | |
| A37 | 5,470,847 | | | Garfield et al. | 11-28-1995 | |
| A38 | 5,681,278 | | | Igo et al. | 10-28-1997 | |
| A39 | 6,475,530 | | | Kuhrt | 11-05-2002 | |
| A40 | 3,291,689 | | | Nordmann | 12-13-1996 | |
| A41 | 6,328,979 | | | Yamashita et al. | 12-11-2001 | |
| A42 | 6,953,593 | | | Kuhrt | 10-11-2005 | |

| | | | | | | | |
|--|---|----|---|-----------------------------|--|------------------|--|
| <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> | | | | Complete if Known | | | |
| | | | | Application Number | | 10/763,358 | |
| | | | | Filing Date | | January 23, 2004 | |
| | | | | First Named Inventor | | Kaesemeyer | |
| | | | | Group Art Unit | | 1614 | |
| | | | | Examiner Name | | Not Yet Assigned | |
| Sheet | 2 | of | 5 | Attorney Docket Number | | 126625.00901 | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|---------------------|----------|-------------------------|--------|----------------------|---|--|---|---|
| | | Office | Number | Kind Code (if known) | | | | |
| B1 | WO | 99/18952 | | | Brigham and Women's Hospital, Inc. | 04-22-1999 | | |
| B2 | WO | 99/47153 | | | Brigham and Women's Hospital, Inc. | 09-23-1999 | | |
| B3 | WO | 00/03746 | | | Brigham and Women's Hospital, Inc. | 01-27-2000 | | |
| B4 | WO | 00/56403 | | | Brigham and Women's Hospital, Inc. | 09-28-2000 | | |
| B5 | EP | 0546796 | A1 | | Ajinomoto | 06-16-1993 | | |
| B6 | WO | 96/00112 | A1 | | Cormedics Corp. | 01-04-1996 | | |
| B7 | WO | 02/00212 | A1 | | Nitrosystems, Inc. | 01-03-2002 | | |
| B8 | WO | 90/11070 | | | Pitman-Moore, Inc. | 10-04-1990 | | |
| B9 | EP | 0350246 | | | Takeda Chemical Industries | 01-10-1990 | | |
| B10 | WO | 01/35953 | | | Kuhrt's | 05-25-2001 | | |
| B11 | WO | 00/56328 | | | Enos Pharmaceuticals, Inc. | 09-20-2000 | | |
| B12 | WO | 98/44893 | | | Kaesemeyer | 10-15-1998 | | |

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|---------------------|----------|---|---|
| Examiner's Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| | C1 | PATEL et al., Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells, 1996, Free Radical Biol. & Med. 20(5):629 (ABSTRACT) | |
| | C2 | LEE et al., Inhibition of Cerebral Neurogenic Vasodilation by L-Glutamine and Nitric Oxide Synthase Inhibitors and Its Reversal by L-Citrulline, 1996, J. Pharmacology and Exper. Thera. 276(2):353-358 | |
| | C3 | ABOU-MOHAMED et al., L-Arginine in the Development and Reversal of Tolerance to Nitroglycerin, 1996, FASEB J. 10(3):A569(no.3280) (ABSTRACT) | |
| | C4 | XIA et al., Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury, June 1996, Proc. Natl. Acad. Sci. USA 93:6770-6774 | |
| | C5 | RECTOR et al., Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients with Heart Failure, June 15, 1996, Circulation 93(12):2135-2141 | |
| | C6 | JEREMY et al., Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit, Aug. 1, 199, Circulation 94(3):498-506 | |
| | C7 | BLOCK et al., Hypoxia Inhibits L-Arginine Uptake by Pulmonary Artery Endothelial Cells, 1995, Am. J. Physiol. 269:L574-L580 (ABSTRACT) | |
| | C8 | HECKER et al., Inhibition of Arginase by NG-Hydroxy-L-Arginine in alveolar macrophages: Implications for the Utilization of L-Arginine for Nitric Oxide Synthesis, Feb. 13, 1995, FEBS Letters 359(2-3):251-254 | |
| | C9 | CLOAREE-BLANCHARD et al., Rapid Development of Nitrate Tolerance in Healthy Volunteers: Assessment Using Spectral Analysis of Short-Term Blood Pressure and Heart Rate Variability, 1994, J. Cardio. Pharm. 24:266-273 (ABSTRACT) | |
| | C10 | CELERMAJER et al., 1994, Role of Endothelium in the Maintenance of Low Pulmonary Vascular Tone in Normal Children, 1994, Circulation 89(5):2041-2044 (ABSTRACT) | |
| | C11 | BOESGAARD et al., Nitrate Tolerance in Vivo is Not Associated with Depletion of Arterial or Venous Thiol Levels, Jan. 1994, Circ. Res. 74(1):115-120 | |
| | C12 | CASTILLO et al., The Plasma Flux and Oxidation rate of Ornithine Adaptively Decline with Restricted with Restricted Arginine Intake, July 5, 1994, Proc. Natl. Acad. Sci. USA 91(14):6393-6397 | |
| | C13 | KUMAGAI et al., Nitric Oxide Increases Renal Blood Flow by Interacting with the Sympathetic Nervous System, Aug. 1994, Hypertension 24(2):220-226 | |

| | | | | | |
|--|---|----|---|-----------------------------|------------------|
| <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> | | | | Complete if Known | |
| | | | | Application Number | 10/763,358 |
| | | | | Filing Date | January 23, 2004 |
| | | | | First Named Inventor | Kaesemeyer |
| | | | | Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned | | | | |
| Sheet | 3 | of | 5 | Attorney Docket Number | 126625.00901 |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | |
| C14 | LIND et al., Endotoxin Stimulates Arginine Transport in Pulmonary Artery Endothelial Cells, 1993, Surgery 114:199-205 (ABSTRACT) | | | | |
| C15 | CASTILLO et al., Splanchnic Metabolism of Dietary Arginine in Relation to Nitric-Oxide Synthesis on Normal Adult Man, Jan. 1, 1993, Proc. Natl. Acad. Sci. USA, 80(1):193-197 (ABSTRACT) | | | | |
| C16 | KITAMURA et al., Nitric Oxide-Mediated Retinal Arteriolar and Arterial Dilatation Induced by Substance P., Sept. 1993, Investig. Ophthal. and Vis. Sci. 34(10):2859-2865 | | | | |
| C17 | MEHTA et al., Free Radicals, Antioxidants and Coronary Heart Disease, Sept. 1993, J. Myocardia Ischemia 5(8):31-33, 31-41 | | | | |
| C18 | WEYRICH et al., The Role of L-Arginine in Ameliorating Reperfusion Injury After Myocardial Ischemia in the Cat, July 1992, Circul. 86(1):279-287 | | | | |
| C19 | SCHINI et al., L-Arginine Evokes Both Endothelium-Dependent and Independent Relaxations in L-Arginine-Depleted Aortas of the Rat, 1991, Circulation Research 68:209-216 (ABSTRACT) | | | | |
| C20 | MARLETTA, Nitric Oxide, Nitrovasodilators and L-Arginine-An Unusual Relationship, Jan. 1991, Western J. Med. 154(1):107-109 | | | | |
| C21 | MAYER et al., Brain Nitric Oxide Synthesis is a Biopterin-and Flavin-Containing Multi-Functional Oido-Reductase, Aug. 1991, FEBS 10045, vol. 288(1,2):187-191 | | | | |
| C22 | ZEMBOWICZ et al., Nitric Oxide and Another Potent Vasodilator are Formed From Nq-Hydroxy-L-Arginine bu Cultured Endothelial Cells, Dec. 1991, Proc. Natl. Acad. Sci. USA, 88:11172-11176 (ABSTRACT) | | | | |
| C23 | SNEDDON et al., Transport and Metabolism of L-Arginine by Bovine Aortic Endothelial Cells, Nitric Oxide From L-Arginine: A Bio-Regulatory System, 1990, Elsevier Sci. Pub., Ch. 51, p. 457 (Intro Only) | | | | |
| C24 | WEIDINGER et al., Persistant Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery, May 1990, Circulation 81(5):1667-1679 | | | | |
| C25 | BREDT et al., Nitric Oxide Mediates Glutamate-Linked Enhancement of cGMP Levels in the Cerebellum, Nov. 1989, Proc. Natl. Acad. Sci. USA 86:9030-9033 | | | | |
| C26 | ALBINA et al., Arginine Metabolism in Wounds, 1988, Am. J. Physiol. 254:E459-E467 | | | | |
| C27 | FLAHERTY et al., Intravenous Nitroglycerin in Acute Myocardial Infarction, Jan. 1975, Circulation 51:132-139 | | | | |
| C28 | PARKER et al., The Arginine Provocative Test: An Aid in the Diagnosis of Hyposematotropism, Aug. 1967, J. Clin. Endo. 27:1129-1136 | | | | |
| C29 | KNOPF et al., Plasma Growth Hormone Response to Intravenous Administration of Amino Acids, Aug. 1965, Preliminary Communication 25:1140-1144 | | | | |
| C30 | COOKE et al., Antatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit, Sept. 1990, J. Clin. Invest. 90(3):1168-1172 | | | | |
| C31 | IGNARRO et al., Basic Polyamino Acids Rich in Arginine, Lysine or Ornithine Cause Both Enhancement of and Refractoriness to Formation of Endothelium-Derived Nitric Oxide in Pulmonary Artery and Vein, Feb. 1989, Circ. Res. 64(2):315-329 | | | | |
| C32 | LIN et al., Prolonged Reduction of High Blood Pressure with Human Nitric Oxide Synthase Gene Delivery, Sept. 1997, Hypertension 30(3):part 1, pp. 307-313 | | | | |
| C33 | GLORIOSO et al., Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients with Essential Hypertension and Primary Hypercholesterolemia, 1999, Hypertension 34:1281-1286 | | | | |
| C34 | CAREY et al., An Arginine-Deficient Diet in Humans Does Not Evoke Hyperammonemia or Orotic Aciduria, 1987, Am. Inst. Nutr. 117(10):1734-1739 | | | | |
| C35 | MATERA et al., Pharmacokinetic Study of the relative Bioavailability and Bioequivalence Afte Oral Intensive or Repeated Short Term Treatment with Two Polyamino Acid Formulations, 1993, Int. J. Clin. Pharm. Res. 13(2):93-105 | | | | |
| C36 | MUROHARA et al., Nitric Oxide Synthase Modulates Angiogenesis in response to Tissue Ischemia, 1998, J. Clin. Invest. 101(11):2567-2578 | | | | |
| C37 | KUROWSKA et al., Hypocholesterolemic properties of nitric oxide. In vivo and in vitro studies using nitric oxide donors, 1998, Biochimica et Biophysica Acta 1392:41-50 | | | | |
| C38 | SUN et al., Pharmacokinetic Interaction Study Between Benazepril and Amlodipine in Healthy-Subjects, 1994, Eur. J. Clin Pharm. 47(3):285 (ABSTRACT) | | | | |

| <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> | | | | Complete if Known | |
|--|------------------|----|---|-----------------------------|------------------|
| | | | | Application Number | 10/763,358 |
| | | | | Filing Date | January 23, 2004 |
| | | | | First Named Inventor | Kaesemeyer |
| | | | | Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned | | | | |
| Sheet | 4 | of | 5 | Attorney Docket Number | 126625.00901 |

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|--|
| C39 | HARIA et al., Pravastatin, A Reappraisal of its Pharmacological Properties and Clinical Effectiveness in the Management of Coronary Heart Disease, 1997, Drugs, 53(2):299-336 |
| C40 | PITT et al., Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events, 1995, JACC 26(5):1133-1139 |
| C41 | NAKAMURA et al., Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIga Pravastatin Study), 1996, Cardiovasc. Drug Ther. 10(4):475-483 (ABSTRACT) |
| C42 | AJI et al., L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL receptor Knockout Mice, 1997, Circulation 95:430-437 |
| C43 | COOKE et al., Arginine: A new Therapy for Atherosclerosis?, 1997, Circulation 95:311-312 |
| C44 | JAY et al., Modulation of Vascular Tone by Low Density Lipoproteins. Effects on L-Arginine Transport and Nitric Oxide Synthesis, 1997, Experimental Physiology, 82:349-360 |
| C45 | VAN BOVAN et al., Reduction of Transient Myocardial Ischemia with Pravastatin in Addition to the Conventional Treatment in Patients with Angina Pectoris, 1996, Circulation 94:1503-1505 |
| C46 | BYINGTON et al., Reduction in Cardiovascular Events During Pravastatin Therapy. Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program, 1995, Circulation 92:2419-2425 |
| C47 | PRITCHARD et al., Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion, 1995, Circ. Res. 77(3):510-518 |
| C48 | LACOSTE et al., Correction of the Increased Thrombogenic Potential with Cholesterol Reduction, 1995, Circulation 92:3172-3177 |
| C49 | VON DER LEYEN et al., Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene, 1995, Proc. Natl. Acad. Sci. USA 92:1137-1141 |
| C50 | EGASHIRA et al., Reduction in Serum Cholesterol with Pravastatin Improves endothelium-Dependent Coronary Vasomotion in Patients with Hypercholesterolemia, 1994, Circulation 89:2519-2524 |
| C51 | TSAO et al., Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine, 1994, Circulation 89:2176-2182 |
| C52 | CHEN et al., Oxidized LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function, 1993, Circulation 93:1740-1746 |
| C53 | HAMON et al., Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury Circulation, Sept. 1994, Circulation 90(3):1357-1362 |
| C54 | COOKE et al., Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta, 1991, Circulation 83:1057-1062 |
| C55 | WITZUM et al., Role of Oxidized Low Density Lipoprotein in Atherogenesis, 1991, J. Clin. Invest. 88:1785-1792 |
| C56 | MUGGE et al., Chronic Treatment with Polyethylene-Glycolated Superoxide Dismutase Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits, 1991, Circ. Res. 69:1293-1300 |
| C57 | FORSTERMANN et al., Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries, 1988, Circ. Res. 62:185-191 |
| C58 | COHEN et al., Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia, 1988, Circ. Res. 63:903-910 |
| C59 | SCHWARZACHER et al., Local Intramural Delivery of L-Arginine Enhances Nitric Oxide Generation and Inhibit Lesion Formation After Balloon Angioplasty, April 1997, Circulation 95(7):1863-1869 |
| C60 | SELLKE et al., Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium, Aug. 1996, Am. J. Physiol. Heart Circ. Physiol. 271:H713-H720 |
| C61 | CUEVAS et al., Hypotensive Activity of Fibroblast Growth Factor, Nov. 1991, Science 254:1208-1210 |
| C62 | BASSENCE, Coronary Vasomotor Responses: Role of Endothelium and Nitrovasodilators, 1994, Cardio. Drugs and Therapy 8:601-610 |
| C63 | SUNDERKOTTER et al., Macrophages and Angiogenesis, 1994, J. Leukoc. Biol. 55(3):410-422 |

| | | | | | |
|--|---|-----------|----------|-------------------------------|------------------|
| <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> | | | | Complete if Known | |
| | | | | Application Number | 10/763,358 |
| | | | | Filing Date | January 23, 2004 |
| | | | | First Named Inventor | Kaesemeyer |
| | | | | Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned | | | | |
| Sheet | 5 | of | 5 | Attorney Docket Number | 126625.00901 |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | |
| C64 | WITZENBICHLER et al., Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia, Aug. 1998, Am. J. Pathol. 153(2):381-394 | | | | |
| C65 | BOUCK et al., How Tumors Become Angiogenic, 1996, Adv. Cancer Res. 69:135-174 | | | | |
| C66 | OGONOWSKI et al., Effect of Nitrite Oxide Donors and Synthase Agonists on Uptake of Cellular L-Arginine, Sept. 1998, Physiobiologist, No. 18.5 (ABSTRACT) | | | | |
| C67 | OGONOWSKI et al., Effect of Nitrite Oxide Donors and Synthase Agonist Peptides on Endothelial Cell Uptake of L-Arginine, March. 1998, FASEB Journal 12(4):A442, No. 2568 (ABSTRACT) | | | | |
| C68 | JIN et al., Effects of Acetylcholine and Prostacyclin on Endothelial Cell Transport of L-Arginine, March 1998, FASEB, No. 2567 (ABSTRACT) | | | | |
| C69 | LAHAM et al., Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery, Nov. 2, 1999, Circulation: 1865-1871 | | | | |
| C70 | TSUTSUMI et al., Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation, Oct. 1999, J. Clinical Invest. 104(7):925-935 | | | | |
| C71 | NIEBAUER et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, 1999, Circulation 100:1830-1835 | | | | |
| C72 | WOLF et al., Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury, March 1995, J. Vasc. Surg. 21:499-504 | | | | |
| C73 | HARRISON, Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis, 1991, J. Am. Coll. Cardiol. 17:71B-76B | | | | |
| C74 | SMITH et al., Tissue plasminogen activator release in vivo in response to vasoactive agents, Oct, 1985, Blood 66(4):835-839 | | | | |
| C75 | FURBERG et al., Effect of lovastatin on early carotid atherosclerosis and cardiovascular events, Oct. 1994, Circulation 90(4): 1679-1687 (ABSTRACT) | | | | |
| C76 | HENDRIKX et al., New Na ⁺ -H ⁺ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca ²⁺ overload in isolated perfused rabbit heart, June 1994, Circulation 89(6):2787-2798 (ABSTRACT) | | | | |
| C77 | JUKEMA et al., Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels, 1995, Circulation 91:2528-2540 (ABSTRACT) | | | | |
| C78 | WATANABE et al., Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance, Oct. 1997, Circulation 96(8):2545-2550 | | | | |
| C79 | FELDMAN et al., Microfabricated Device for Intravascular Delivery, 1998, J. Am. Coll. Card. 31(2): 351A (870-6) | | | | |
| C80 | MOLLACE et al., Evidence that L-arginine possesses proconvulsant effects mediated through nitric-oxide, 1991, Neuroreport 2(5):269-272 (ABSTRACT) | | | | |
| C81 | CONTE et al., Press-coated tablets for time-programmed release of drugs, 1993, Biomaterials 14(13):1017-1023 | | | | |
| C82 | FEELISCH et al., Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells, 1991, Biochem. and Biophys. Res. Comm. 180:Nc:286-293 | | | | |
| C83 | LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets, 2nd ed., 1990 (TOC) | | | | |
| C84 | GENNARO et al. eds., Remington's Pharmaceutical Sciences, 18th ed., 1990, Mack Pub. Co. (TOC) | | | | |
| C85 | O'DRISCOLL et al., Simvastatin, an HMG-Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month, 1997, Circulation 95:1126-1131 (ABSTRACT) | | | | |
| C86 | LUSCHER et al., Lipids and endothelial function: effects of lipid lowering and other therapeutic interventions, 1996, Curr. Op. Lipid. 7:234-240 | | | | |
| C87 | SEARLES et al., The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice, Oct. 1999, J. Clin. Investigation 104(8):1013-1014 | | | | |
| C88 | MUSCELLA et al., Angiotensin II Stimulates the Na ⁺ /H ⁺ Exchanger in Human Umbilical Vein Endothelial Cells Via At1 Receptor, 1999, Life Sci. 65(22):2385-2394 | | | | |
| C89 | DINERMAN et al., Molecular Mechanisms of Nitric Oxide Regulation, 1993, Circul. Res. 73(2):217-222 | | | | |